Pharmacotherapy of Neuropathic Pain

JOURNAL TITLE: Bengal Physician Journal

Author
1. Anup K Bhattacharya
2. Shouvik Choudhury
3. Hindol Mondal
4. Abhijit Das
ISSN
DOI
10.5005/jp-journals-10070-6114
Volume
6
Issue
2
Publishing Year
2019
Pages
2
Author Affiliations
1. com.mps.common.model.Contributor@347f241f ,
2. com.mps.common.model.Contributor@79e8b677 ,
3. com.mps.common.model.Contributor@3d7d9e9f ,
4. com.mps.common.model.Contributor@cd25638
Article keywords
Capsaicin, Gabapentinoid, Neuropathic pain, Serotonin–noradrenaline reuptake inhibitor, Tricyclic antidepressant

Abstract

Neuropathic pain (NP), comprising a range of heterogeneous pathophysiological conditions, is often difficult to manage despite a number of treatment guidelines have been published worldwide. Most of the available treatments in these guidelines have moderate efficacy and present side effects that limit their use. Currently, there is a general agreement on appropriate first-line treatment of NP, whereas debate continues regarding second- and third-line treatments. First-line drugs include antidepressants (tricyclic antidepressants (TCAs) and serotonin–noradrenaline reuptake inhibitors (SNRIs)) and gabapentinoids. Second- and third-line drugs for NP include topical lidocaine, topical capsaicin, anticonvulsants, and opioids. A good understanding of pathophysiology of NP with the mechanism of action of currently available drugs along with their side effect profile helps to tailor therapies both to the specific neuropathic disease and to the needs of an individual patient. This review provides an overview of current drugs available for the treatment of NP with an emphasis on their mechanism of action.

© 2019 Jaypee Brothers Medical Publishers (P) LTD.   |   All Rights Reserved

Powered by MPS ScholarStor